Results 241 to 250 of about 1,923,312 (279)

Respiratory Syncytial Virus Vaccine Effectiveness Among US Older Adults, 2023-2024 Season.

JAMA Netw Open
Lu Y, Smith ER, McEvoy R, Spencer MRT, Lindaas AF, Izurieta HS, Zhang Y, Zhang HT, Wagner E, Menis M, Naik NM, Steele WR, Wernecke M, Chillarige Y, Anderson SA, Forshee RA.   +15 more
europepmc   +1 more source

Advances in the prevention of respiratory syncytial virus infection in children. [PDF]

J Bras Pneumol
Krey JG, Manfroi L, Damian FB, Pinto LA, Scotta MC.   +4 more
europepmc   +1 more source

Respiratory syncytial virus (RSV) and RSV vaccines [PDF]

core  

Human Respiratory Syncytial Virus in Vaccinated and Unvaccinated Adults, Georgia, USA, 2024-2025. [PDF]

Emerg Infect Dis
Rachida S, Ahmed A, Rojas-Gallardo D, Tafesse H, Dakanay H, Duford M, Tolbert C, Springfield RS, Piantadosi A.   +8 more
europepmc   +1 more source

Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Older Adults in the Netherlands. [PDF]

Infect Dis Ther
Langedijk AC, van den Dungen F, Franssen FME, Goeijenbier M, Averin A, Quinn E, Atwood M, Mendes D.   +7 more
europepmc   +1 more source

First Report on Remdesivir Use for the Treatment of Respiratory Syncytial Virus in Five Allogeneic Hematopoietic Cell Transplant Recipients. [PDF]

J Infect Dis
McCulloch DJ, Khawaja F, Tverdek FP, Ford ES, Vora SB, Waghmare A, Vuong N, Chemaly RF, Hill JA.   +8 more
europepmc   +1 more source

Screening of key host targets and mechanistic assessment of berberine modulation of host responses to respiratory syncytial virus. [PDF]

J Int Med Res
Shen M, Xia J.
europepmc   +1 more source